Orexigen (OREX) Volatility, Shares Rise Following Positive Contrave Trial News
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Join SI Premium – FREE
Orexigen Therapeutics, Inc. (Nasdaq: OREX) is moving higher early Wednesday, following faster than expected enrollment in its Light Study, the Contrave cardiovascular outcomes clinical trial.
Implied volatility is up 1.3 percent from Tuesday's close and at 90 percent of its trailing annual average.
Shares are about 6.5 percent higher on the session.
Implied volatility is up 1.3 percent from Tuesday's close and at 90 percent of its trailing annual average.
Shares are about 6.5 percent higher on the session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: Iran conflict is working out very well, talks going on at request of Iran
- Eli Lilly & Co. (LLY) call put ratio 1 call to 1.5 puts with into quarter results
- Toast (TOST) call put ratio 1.3 calls to 1 put into quarter results
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers, OptionsRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
